Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979505 · ClinicalTrials.gov registry record · Phase 2
GV101 in Healthy Obese Participants
A Phase 2 study of Weight Management, sponsored by Graviton Bioscience Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
- 20
- Study locations
NCT06979505: Completed Phase 2 study of Weight Management, sponsored by Graviton Bioscience Corporation.
NCT06979505 is a Phase 2 study of Weight Management that has completed, run by Graviton Bioscience Corporation. The registered enrollment target is 131 participants, below the 852-participant average among 8 other Weight Management trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06979505, a Phase 2 study of Weight Management, has completed, sponsored by Graviton Bioscience Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.
Conditions Studied
Interventions
- DRUG GV101
- DRUG GV101 placebo
Study Locations (20)
Israel
- Hadassah Medical Center Ein Karem - Jerusalem
- Hasharon Hospital - Petah Tikva
- Rabin Medical Center, Beilinson Hospital - Petah Tikva
- Sheba Medical Center - Tel Litwinsky
California
- Catalina Research Institute, LLC - Montclair
- Encompass Clinical Research - Spring Valley
Missouri
- Study Metrix Research - City of Saint Peters
- Kansas City Research Institute - Kansas City
Utah
- Advanced Research Institute - Ogden - Ogden
- Chrysalis Clinical Research - St. George
Alabama
- Lakeview Clinical Research, LLC - Guntersville
Arizona
- Arizona Clinical Trials - Tucson
Kentucky
- Louisville Metabolic and Atherosclerosis Research Center (L-MARC) - Louisville
Louisiana
- Tandem Clinical Research - Marrero
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2026-01-28 |
| Phase | Phase 2 |
What the finished NCT06979505 record still lists
NCT06979505 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 852-participant average among 8 other Weight Management trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Weight Management appearing as the primary indexed condition, and to 2 interventions - of which GV101 is the first listed.
NCT06979505 names 20 study sites across 14 states, led by Israel, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT06979505 about?
NCT06979505 is a clinical study titled "GV101 in Healthy Obese Participants". The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.
What is the current status of trial NCT06979505?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2025-06-30. Estimated completion is 2026-01-28.
What conditions does trial NCT06979505 study?
This clinical trial studies the following conditions: Weight Management.
What interventions are being tested in trial NCT06979505?
The interventions under investigation include: GV101 (DRUG), GV101 placebo (DRUG).
Who is sponsoring clinical trial NCT06979505?
This trial is sponsored by Graviton Bioscience Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06979505 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06979505's enrollment target sits among peer trials
131 4th of 8 higher than 5 of 8 other Weight Management trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Management trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
COMPLETED · Phase 2
-
Weight Loss Management in Endometrial Cancer Survivors
RECRUITING
-
Advancing Biopsychosocial Care Training Initiative
RECRUITING · NA
-
How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types
RECRUITING · NA
-
Weight Management After Cancer for Survivors in Rural Communities
RECRUITING · NA
-
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI